Hextar Healthcare Berhad, an investment holding company, (7803) Fair Value & Analysis
Basic Materials · MY · Market cap 60.6M MYR
Fair value as of: Jul 19, 2026
From 7 valuation models · updated 22 days ago
Fair value updated Jul 19, 2026, revised from 0.1200 MYR to 0.1128 MYR (−6.0%) since Jun 26, 2026.
Below-average quality, screening 88% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (39/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (0.0908 MYR). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range 0.0550 MYR – 1.47 MYR · fair‑value band 0.0908 MYR – 0.1348 MYR · the 0.0600 MYR price screens below the 0.1128 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.
Analysis
Hextar Healthcare Berhad, an investment holding company, (7803) currently trades at 0.0600 MYR, while our model-based Fair Value estimate is 0.1128 MYR, implying the stock looks roughly 88.0% undervalued today. The Quality Score stands at 39/100 (below-average quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Hextar Healthcare Berhad, an investment holding company, generated revenue of 144M MYR at a net margin of -30.6%. Revenue declined 17.5% year over year. It earns a return on equity of -9.2%. The balance sheet holds a net cash position of 19.6M MYR. Fundamentals as of Jul 19, 2026
Our scenario range runs from 0.0908 MYR (bear case) to 0.1348 MYR (bull case); at 0.0600 MYR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 50% below its 52-week high, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -58% fair-value upside, at 88%, 7803 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 7 models by family
Widest divergence: Asset-Based (0.2700 MYR) versus DCF Models (0.1200 MYR). Highest evidence: Growth DCF (80).
Notify me when 7803 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 20
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Hextar Healthcare Berhad, an investment holding company, produces, sells, and exports general-purpose gloves, industrial gloves, and nitrile disposable gloves in Europe, Asia, North and South America, and internationally. It operates through Gloves Operation, Medical Devices Operation, and Investment Holding segments.
Full company description
Hextar Healthcare Berhad, an investment holding company, produces, sells, and exports general-purpose gloves, industrial gloves, and nitrile disposable gloves in Europe, Asia, North and South America, and internationally. It operates through Gloves Operation, Medical Devices Operation, and Investment Holding segments. The company offers latex, neoprene, nitrile, and two tone gloves. It also manufactures and trades in in-vitro diagnostics rapid test kits and enzyme-linked immunosorbent assay test kits for detection and diagnoses of infectious diseases and drug-of-abuse screening for medical professionals and the clinical diagnostic markets. In addition, the company is involved in the trading of gloves, household and kitchen items, and personal protective products. Hextar Healthcare Berhad was founded in 1987 and is headquartered in Ipoh, Malaysia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hextar Healthcare Berhad, an investment holding company, reported revenue of 148M MYR in FY2025 versus 515M MYR in FY2021, a compound −26.8%/yr. Reported net income was −45.0M MYR in FY2025.
Watch 7803: get an alert when its fair value changes →
Peer Group
Specialty Chemicals · 673 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Specialty Chemicals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $489.98 | $222.03 | -55% |
| Nan Ya Plastics Corporation 1303 | 181.50 TWD | 255.83 TWD | +41% |
| Wanhua Chemical Group 600309 | ¥70.04 | ¥68.03 | -3% |
| Novozymes A/S NSISB | kr 428.20 | kr 179.66 | -58% |
| Asian Paints Limited ASIANPAINT | ₹2,689 | ₹668.81 | -75% |
| Solar Industries India Limited SOLARINDS | ₹18,236 | ₹2,793 | -85% |
| Pidilite Industries Limited PIDILITIND | ₹1,560 | ₹351.84 | -77% |
| PT Chandra Asri Pacific Tbk TPIA | 1,805 IDR | 2,888 IDR | +60% |
| Linde India Limited LINDEINDIA | ₹7,115 | ₹757.93 | -89% |
| Berger Paints India Limited BERGEPAINT | ₹493.70 | ₹164.29 | -67% |
Compare Hextar Healthcare Berhad, an investment holding company, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Hextar Healthcare Berhad, an investment holding company, (7803) overvalued or undervalued?
What is the fair value of 7803?
What is the quality score of 7803?
What is the revenue of Hextar Healthcare Berhad, an investment holding company, (7803)?
What is the net profit margin of 7803?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Hextar Healthcare Berhad, an investment holding company, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.